- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03359577
Clinical Study to Investigate Psorax35 Supplementation in Patients With Psoriasis
Randomized, Double Blind, Placebo Controlled Clinical Study to Investigate Efficacy of Psorax35 for Treatment of Psoriasis
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Psoriasis is a common, genetically predisposed, inflammatory and proliferative disease of the skin, the most characteristic lesions consisting of chronic, sharply demarcated, dull-red scaly plaques, particularly on extensor parts of limbs and in the scalp. Psoriasis can be divided into mild, moderate or severe psoriasis based on the extent of the skin changes
Psorax35, which is extracted from herring roe are shown to improve the condition of people with psoriasis.
The objective of this study is to investigate the effect, safety, and mechanism of action of Psorax35 on mild to moderate Psoriasis and comorbidities associated with psoriasis through a 32-weeks study.
The participants will be randomized into one of two arms; Psorax35 and Placebo. The study will include a total of 6 treatment visits involving Blood samples, Photo documentation, Psoriasis and Severity index (PASI), Body surface area (BSA), Physician's Static Global Assessment (PSGA), Life quality index (EQ-5D, VAS and DLQI), Blood pressure, Blood rate, Body Mass Index (BMI), Waist circumference, Waist/hip ratio, and 24 hrs dietary recall. At visit 4 Blood samples, Blood pressure, Blood rate, BMI, Waist circumference, Waist/hip ratio, and 24 hrs dietary recall are not included.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Bergen, Norway, 5021
- Haukeland Universitetssjukehus
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Female and male subjects at least 18 years old understanding Norwegian oral and written information
Diagnosis of mild to moderate psoriasis vulgaris for at least 6 months prior to mild to moderate Psoriasis vulgaris as defined at screening by:
- PASI scores less than 10 (mild psoriasis) and
- Body surface area affected by chronic plaque psoriasis 1%-9.9% (mild and moderate psoriasis)
- Women of childbearing potential must have a negative serum pregnancy test at the screening visit.
Exclusion Criteria:
- Pregnancy
- Initiation of a drug known to cause or exacerbate psoriasis
- Having received an investigational medical product (IMP) or investigational device within 28 days' prior randomization
- Alcohol and drug abuse or any condition associated with poor compliance
- Malabsorption disorder
- Scheduled hospitalization during the course of the study that could compromise the study
- Major diseases or infections
- Known or suspected sensitivity or allergic reactions to the IMP or excipients
- Presence of other major medical or psychiatric illness that would affect the ability to participate in the study or put the subject at increased risk
- Planned trip abroad to a sunny resort involving active sun exposure
- Any anti psoriatic treatment
- Immunosuppressive - immunomodulating treatment given for any other reason than psoriasis
- UV treatment and return from a sunny resort involving active sun exposure for the last 4-6 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Psorax35
Food supplement Psorax35 capsules containing fish roe extract high in eicosapentaenoic acid (EPA)/docosahexaenoic acid (DHA) phospholipid.
Dose: 10 capsules of 590 mg.
Route of administration: oral.
|
This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis.
Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
|
Placebo Comparator: MCT oil
Placebo capsules containing coconut oil high in caprylic acid C8:0 and capric acid C10:0 (Medium Chain triglycerides (MCT) oil).
Dose: 10 capsules of 590 mg: Route of administration: oral.
|
This is a randomized, 32 weeks, single center, placebo controlled, double blind study to investigate Psorax35 supplementation in patients with mild to moderate Psoriasis.
Groups of patients will be block randomized using randomly selected block sizes, and stratified according to gender.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PASI
Time Frame: Baseline to 32 weeks
|
Change from baseline in PASI in the Psorax35 group as compared to Placebo at week 32.
|
Baseline to 32 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in PASI over 24 weeks
Time Frame: Baseline to 24 weeks
|
Change from baseline in PASI in the Psorax35 group as compared to Placebo at week 6, 12, 18, and 24.
|
Baseline to 24 weeks
|
Number of patients achieving PASI<3
Time Frame: Baseline to 32 weeks
|
Number of patients achieving PASI<3 in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.
|
Baseline to 32 weeks
|
Improvement in PASI
Time Frame: Baseline to 32 weeks
|
Difference in 50% improvement in PASI (PASI-50), difference in 75% improvement in PASI (PASI-75) and difference in 90% improvement in PASI (PASI-90) from baseline in the Psorax35 group as compared with Placebo group at week 6, 12, 18, 24, and 32.
|
Baseline to 32 weeks
|
Change in Physician's Static Global Assessment (PSGA)
Time Frame: Baseline to 32 weeks
|
Changes from baseline in PSGA=0-1 demonstrating clear or almost clear skin in the Psorax35 group as compared to Placebo group at week 6, 12, 18, 24, and 32.
|
Baseline to 32 weeks
|
Change in Dermatology Life Quality Index (DLQI)
Time Frame: Baseline to 32 weeks
|
Changes from baseline in DLQ index in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.
|
Baseline to 32 weeks
|
Change in EuroQoL 5 index (EQ-5D)
Time Frame: Baseline to 32 weeks
|
Change from baseline in EuroQoL 5 index in the Psorax35 group as compared to Placebo group at week 6, 12, 18, 24, and 32.
|
Baseline to 32 weeks
|
Change in Visual analogue scale (VAS) score
Time Frame: Baseline to 32 weeks
|
Changes from baseline in VAS Scores (pruritus, pain skin/joints, stinging and total health condition (general/skin)) in the Psorax35 group as compared to Placebo at week 6, 12, 18, 24, and 32.
|
Baseline to 32 weeks
|
Changes in highly sensitive C-reactive protein
Time Frame: Baseline to 32 weeks
|
Changes from baseline in highly sensitive C-reactive protein (mg/L) in the Psorax35 group as compared to Placebo at week 12, and 32.
|
Baseline to 32 weeks
|
Adverse Events (AE) and Severe Adverse Events (SAE)
Time Frame: Baseline to week 32
|
Monitoring of AEs and SAEs.
|
Baseline to week 32
|
Changes in fasting serum lipids
Time Frame: Baseline to 32 weeks
|
Changes from baseline in serum lipids (Triacylglycerol (TAG), total cholesterol (TK), HDL-cholesterol, LDL-cholesterol, free-cholesterol, phospholipids, non-esterified fatty acids, non-HDL-cholesterol - mmol/L) and lipid ratios (TAG/TK ratio, HDL-chol/LDL-chol ratio), in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.
|
Baseline to 32 weeks
|
Changes in fasting serum glucose
Time Frame: Baseline to 32 weeks
|
Changes from baseline in serum glucose (mmol/L) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32
|
Baseline to 32 weeks
|
Changes in fasting serum insulin and insulin C-peptide
Time Frame: Baseline to 32 weeks
|
Changes from baseline in serum insulin (mIE/L) and insulin C-peptide (nmol/L) in the Psorax35 group as compared to Placebo at week 12, and 32.
|
Baseline to 32 weeks
|
Changes in fasting serum HbA1c
Time Frame: Baseline to 32 weeks
|
Changes from baseline in serum HbA1c (%) in the Psorax35 group as compared to Placebo at week 12, and 32.
|
Baseline to 32 weeks
|
Changes in blood pressure
Time Frame: Baseline to 32 weeks
|
Changes from baseline in blood pressure (mmHg) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.
|
Baseline to 32 weeks
|
Changes in heart rate
Time Frame: Baseline to 32 weeks
|
Changes from baseline in heart rate (bpm) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32.
|
Baseline to 32 weeks
|
Changes in Body Mass Index (BMI)
Time Frame: Baseline to 32 weeks
|
Changes from baseline in Body Mass Index (BMI) in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32. Weight in kilograms and height in meters will be combined to report BMI in kg/m2 |
Baseline to 32 weeks
|
Changes in waist/hip ratio
Time Frame: Baseline to 32 weeks
|
Changes from baseline in waist/hip ratio in the Psorax35 group as compared to Placebo at week 6, 12, 24, and 32. Waist in centimeters and hip in centimeters will be combined to report waist/hip ratio. |
Baseline to 32 weeks
|
Changes in plasma cytokines including adipocytokines
Time Frame: Baseline to 32 weeks
|
Changes from baseline in plasma cytokines including adipocytokines (pg/mL) in the Psorax35 group as compared to Placebo group at week 12, and 32.
|
Baseline to 32 weeks
|
Changes in serum antioxidant capacity
Time Frame: Baseline to 32 weeks
|
Changes from baseline in serum antioxidant capacity (nmol Trolox ekv./ul) in the Psorax35 group as compared to Placebo group at week 12, and 32.
|
Baseline to 32 weeks
|
Changes in serum Vitamin D
Time Frame: Baseline to 32 weeks
|
Changes from baseline in serum Vitamin D (nmol/L) in the psorax35 group as compared to Placebo group at week 12, and 32.
|
Baseline to 32 weeks
|
Difference in use of cream-based treatment
Time Frame: Baseline to 32 weeks
|
Difference in use of rescue medication from baseline in the Psorax35 group as compared to placebo group at week 6, 12, 18, 24, and 32. Amount of cream-based treatment in grams and number of days treated will be combined to report the use. |
Baseline to 32 weeks
|
Changes in safety laboratory parameters including hematology, clinical chemistry
Time Frame: Baseline to 32 weeks
|
Changes from baseline in safety laboratory parameters including hematology (Hemoglobin-g/dL, Hematocrit, Erythrocytes-10^9/L, Leukocytes-10^9/L, Lymphocytes-10^9/L, Monocytes-10^9/L, Eosinophiles-10^9/L, Neutrophiles-10^9/L, Blood plates-10^9/L), and clinical chemistry (ALAT-u/L, lactate dehydrogenase-u/L, creatine kinase-u/L, creatinine-umol/L, gamma-glutamyltransferase-u/L).
|
Baseline to 32 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Rolf Berge, PhD, University of Bergen
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Psorax35-H17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Psoriasis Vulgaris
-
LEO PharmaCompletedPlaque Psoriasis | Psoriasis VulgarisGermany
-
SoligenixRecruitingPsoriasis | Plaque Psoriasis | Psoriasis VulgarisUnited States
-
LEO PharmaTerminatedPsoriasis | Plaque Psoriasis | Psoriasis VulgarisBelgium, Germany, Italy, Spain, Denmark, Austria, France, Greece, Switzerland, United Kingdom, Netherlands, Sweden
-
PRCL Research Inc.CompletedPlaque Psoriasis | Psoriasis VulgarisCanada, Slovakia, Ukraine
-
University of California, San FranciscoTerminatedPlaque Psoriasis | Psoriasis VulgarisUnited States
-
Chinese University of Hong KongNot yet recruitingPsoriasis Vulgaris
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University Hospital, GhentRecruitingPsoriasis VulgarisBelgium
-
University of California, San FranciscoNovartis Pharmaceuticals; National Psoriasis FoundationRecruitingPsoriasis VulgarisUnited States
-
University of California, San FranciscoSun Pharmaceutical Industries LimitedRecruiting